raloxifene hydrochloride has been researched along with atorvastatin in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Cassels, A; Cole, C; Hughes, MA; Lexchin, J; McCormack, JP; Mintzes, B | 1 |
| Economidou, O; Kalofoutis, A; Kalofoutis, C; Piperi, C; Skenderi, K | 1 |
| Kalofoutis, A; Kalofoutis, C; Lagogianni, I; Piperi, C; Troupis, G | 1 |
| Tsakok, AD | 1 |
| Kalofoutis, A; Kalofoutis, C; Piperi, C; Skenderi, K; Zisaki, K | 1 |
| Baytur, Y; Demir, BC; Gumuser, G; Inceboz, U; Ozbilgin, K; Uyar, Y | 1 |
| Cetinkaya Demir, B; Köse, C; Ozbilgin, K; Uyar, Y | 1 |
| Dhanaraj, P; Israel, EVMV; Paulraj, MS; Sudha, N; Yousuf, S | 1 |
| Bram, Y; Chen, S; Copertino, DC; Duarte, RRR; Han, Y; Iñiguez, LP; Marston, JL; Nixon, DF; Powell, TR; Schwartz, RE | 1 |
1 trial(s) available for raloxifene hydrochloride and atorvastatin
| Article | Year |
|---|---|
Beneficial effects of raloxifene and atorvastatin on serum lipids and HDL phospholipids levels of postmenopausal women.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Postmenopause; Pyrroles; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome; Triglycerides | 2004 |
8 other study(ies) available for raloxifene hydrochloride and atorvastatin
| Article | Year |
|---|---|
Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs.
Topics: Acetamides; Advertising; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antiviral Agents; Atorvastatin; Bibliometrics; Canada; Celecoxib; Cholinesterase Inhibitors; Consumer Product Safety; Disclosure; Donepezil; Drug Industry; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Estrogen Antagonists; Heptanoic Acids; Humans; Indans; Newspapers as Topic; Oseltamivir; Patient Education as Topic; Piperidines; Pyrazoles; Pyrroles; Raloxifene Hydrochloride; Sulfonamides | 2003 |
Comparison of raloxifene and atorvastatin effects on serum lipids composition of healthy post-menopausal women.
Topics: Adult; Aged; Atorvastatin; Female; Heptanoic Acids; Humans; Lipid Metabolism; Lipids; Middle Aged; Postmenopause; Pyrroles; Raloxifene Hydrochloride | 2004 |
Beneficial effects of raloxifene and atorvastatin on serum lipids.
Topics: Anticholesteremic Agents; Atorvastatin; Confounding Factors, Epidemiologic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Pyrroles; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2005 |
Evidence of improved serum fatty acid profile of postmenopausal women receiving atorvastatin and raloxifene.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Drug Therapy, Combination; Fatty Acids; Female; Heptanoic Acids; Humans; Middle Aged; Postmenopause; Pyrroles; Raloxifene Hydrochloride; Risk; Treatment Outcome | 2005 |
Comparative effects of risedronate, atorvastatin, estrogen and SERMs on bone mass and strength in ovariectomized rats.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Bone Density; Bone Density Conservation Agents; Clomiphene; Estrogens; Etidronic Acid; Female; Femur; Heptanoic Acids; Osteoporosis; Ovariectomy; Pyrroles; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Risedronic Acid; Selective Estrogen Receptor Modulators; Tibia | 2009 |
Effect of raloxifene and atorvastatin in atherosclerotic process in ovariectomized rats.
Topics: Animals; Aorta, Thoracic; Atherosclerosis; Atorvastatin; Chemokine CCL2; Endothelium, Vascular; Estrogen Antagonists; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Ovariectomy; Pyrroles; Raloxifene Hydrochloride; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha | 2013 |
On the accessibility of surface-bound drugs on magnetic nanoparticles. Encapsulation of drugs loaded on modified dextran-coated superparamagnetic iron oxide by β-cyclodextrin.
Topics: Atorvastatin; beta-Cyclodextrins; Dextrans; Drug Compounding; Magnetite Nanoparticles; Magnetometry; Microscopy, Electron, Scanning; Pharmaceutical Preparations; Photoelectron Spectroscopy; Raloxifene Hydrochloride; Silybin; Silymarin; Spectrometry, Fluorescence; Surface Properties; X-Ray Diffraction | 2016 |
Identifying FDA-approved drugs with multimodal properties against COVID-19 using a data-driven approach and a lung organoid model of SARS-CoV-2 entry.
Topics: Antiviral Agents; Atorvastatin; Cell Line; Coronavirus 3C Proteases; Coronavirus RNA-Dependent RNA Polymerase; COVID-19; COVID-19 Drug Treatment; Doxycycline; Drug Approval; Drug Repositioning; Gene Expression Regulation; Humans; Lung; Models, Biological; Molecular Docking Simulation; Organoids; Raloxifene Hydrochloride; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Trifluoperazine; United States; United States Food and Drug Administration; Vesiculovirus; Virus Internalization | 2021 |